BIOFLOR

This brand name is authorized in Nigeria. It is also authorized in Cyprus, Hong Kong SAR China, Malta, Singapore.

Active ingredients

The drug BIOFLOR contains one active pharmaceutical ingredient (API):

1	Saccharomyces boulardii CNCM I-745 UNII 978D8U419H - SACCHAROMYCES CEREVISIAE
	Saccharomyces boulardii is an intestinal flora replacement which acts as antidiarrheal microorganisms in the digestive tract. During transit under its viable form in the digestive tract, saccharomyces boulardii exerts biological actions which are similar to the protective properties of the normal intestinal flora.
	Read more about Saccharomyces boulardii

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-5491	Powder for solution	BIOFLOR 100MG POWDER FOR ORAL SOLUTION PWD_F_SOL 100 mg 1x20Sachets	64 RNW-PP-263255 BIOFLOR 100MG POWDER FOR ORAL SOLUTION. SACCHAROMYCES BOULARDII 100MG LYOPHILIZED SACCHAROMYCES BOULARDII .............113.00 MG (MIXTURE OF 100 MG OF LYOPHILIZED YEAST CELLS AND 13 MG OF LACTOSE). EXCIPIENTS: FRUCTOSE, ANHYDROUS COLLOIDAL SILICA, TUTTI FRUTTI AROMA. TO ONE SACHET OF 306.00 MG A4-5491 Drugs Imported Products 1x,20Sachets Over The Counter (OTC) 6/15/2022 MERIT HEALTHCARE LIMITED, DELE ASHIRU STREET, IRE-AKARI ESTATE ISOLO LAGOS 8171273639 casmolar1@yahoo.com Biocodex, 1, avenue Blaise Pascal 60 000 Beauvais France., France	30/11/2023

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BIOFLOR Powder for oral suspension	MPI, EU: SmPC	Υπουργείο Υγείας (CY)
BIOFLOR Capsule, hard	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A07FA02	Saccharomyces boulardii	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07F Antidiarrheal microorganisms → A07FA Antidiarrheal microorganisms
Discover more medicines within A07FA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	30568, 41663
MT	Medicines Authority	MA239/00101, MA239/00102, MA239/00103
NG	Registered Drug Product Database	A4-5491
SG	Health Sciences Authority	14722P, 14986P